Jump to content
  • rrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

    Legal Disclaimer

    All use of the Rosacea Research & Development Institute (RRDi or irosacea.org) Web site is subject to the terms and conditions set forth below. When referring to the Rosacea Research & Development Institute (RRDi or irosacea.org) in this legal discaimer includes the following domains:


    Any use of such Web pages constitutes the user's agreement to abide by the following terms and conditions.

    The Rosacea Research & Development Institute [RRDi] is a non profit corporation registered in the states of Alabama and Hawaii, USA as well as recognized June 7, 2004 by the USA Internal Revenue Service as a 501 (c) (3) non profit tax exempt organization.

    All medical information on this Web site has been reviewed for accuracy. However, the information posted here by the Rosacea Research & Development Institute or any third party should not be considered medical advice, nor is it intended to replace consultation with a qualified physician. The Institute does not evaluate, endorse or recommend any particular medications, products, equipment or treatments. Rosacea may vary substantially from one patient to another, and treatment must be tailored by a physician for each individual case.

    Links to other Web sites found on irosacea.org are provided as a service to our users. Such linkage does not constitute endorsement of the site by the Rosacea Research & Development Institute, and the Institute is not responsible for the content of external web sites. Links to commercial rosacea web sites are prohibited at this time.

    The Rosacea Research & Development Institute Web pages are designed for educational purposes only. This information is not intended to substitute for informed medical advice. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified health care provider. The Rosacea Research & Development Institute does not endorse or attest to the validity or accuracy of any treatments or medications discussed herein. Before acting on any information contained on the Web pages, you agree that you will consult your health care provider to determine whether the information you are relying on is appropriate for your medical condition.

    All information provided by the Rosacea Research & Development Institute is owned by or licensed to the Rosacea Research & Development Institute. The Rosacea Research & Development Institute retains all proprietary rights to the information contained on the pages. Except for making one hard copy print of the information or downloading the material for a one-time use, information on the pages may not be reproduced, transmitted, distributed, or displayed, without the express consent of the Rosacea Research & Development Institute.



    The RRDi does not knowlingly use any material (images or text) that is copyrighted by others. If you believe any materials accessible on or from this web site infringe your copyright, you may request removal of those materials (or access thereto) from this web site by the RRDi copyright agent (identified below) and providing the following information:
    Identification of the copyrighted work that you believe to be infringed. Please describe the work, and where possible include a copy or the location (e.g., URL) of an authorized version of the work. Identification of the material that you believe to be infringing and its location. Please describe the material, and provide us with its URL or any other pertinent information that will allow us to locate the material. Your name, address, telephone number and (if available) e-mail address.
    A statement that you have a good faith belief that the complained of use of the materials is not authorized by the copyright owner, its agent, or the law.
    A statement that the information that you have supplied is accurate, and indicating that "under penalty of perjury," you are the copyright owner or are authorized to act on the copyright owners behalf.

    A signature or the electronic equivalent from the copyright holder or authorized representative.

    The irosacea.org agent for copyright issues relating to this web site is as follows:

    RRDi Copyright Agent
    PO Box 858
    Centre, Alabama, 35960

    Or use our contact form explaining your copyright issue with our website. We will handle such matters in an appropriate and timely manner. 

    In an effort to protect the rights of copyright owners, the irosacea.org maintains a policy for the termination, in appropriate circumstances, of subscribers and account holders of this web site who are repeat infringers.

    International Disclaimer

    This Web site can be accessed from other countries around the world and may contain references to rosacea products, services, treatments or programs that have not been announced in your country. These references do not imply that irosacea.org intends to announce such products, services or programs in your country.

    Governing Law and Jurisdiction

    This web site (excluding linked sites) is controlled by irosacea.org from its office within the state of Hawaii, United States of America. By accessing this Web site, you and irosacea.org agree that all matters relating to your access to, or use of, this Web site shall be governed by the statutes and laws of the state of Hawaii, without regard to the conflicts of laws principles thereof. You and irosacea.org also agree and hereby submit to the exclusive personal jurisdiction and venue of the Superior Court of the District of Honolulu, Honolulu County and the United States District Court for the District of Hawaii with respect to such matters. irosacea.org makes no representation that materials on this Web site are appropriate or available for use in other locations, and accessing them from territories where their contents are illegal is prohibited. Those who choose to access this site from other locations do so on their own initiative and are responsible for compliance with local laws.

    Privacy Policy

    Our Privacy Policy is the commitment to respect the privacy of the information entrusted to our institute with your personal information by not giving your personal information to others or using it inappropriately. If you have any questions or concerns regarding our privacy policy please direct them to privacy@irosacea.org

    You may also send a letter to:

    Rosacea Research & Development Institute, PO Box 858, Centre, Alabama 35960

    irosacea.org does not sell, exchange, or release your personal information (name, e-mail address, mailing address, credit card data, etc.) without your consent to any third parties.

    Information gathered through the use of cookies is not related to any personally identifiable details.

    What information does irosacea.org collect from our users and how do we collect it?

    irosacea.org only contacts individuals who specifically request that we do so. irosacea.org collects personally identifying information from our users during (1) online registration, (2) online public surveys, (3) online purchasing, and (4) messages posted to our public forum board and the private forum. Generally, this information includes name, e-mail address, postal address, and answers to public survey questions. This information is used for internal purposes and helps us determine how to continually improve our site and the institute. Names and email addresses may be posted in public forums and public databases by individual members who post such information on their own. The RRDi is not responsible if a member posts their own real name, address, phone number, or email address. If a member later regrets posting this information the member can report where the post is and have it removed upon request. If you do not want your name listed in any of the public surveys or databases you should use a bogus name or alias (nickname) since the institute is not responsible if you use your real name or email address in a public survey or database. However, the institute will not publicly display any of the members names, email addresses or postal addresses. Each member is responsible for his or her own privacy when using any of the institute's web site when posting. Non voting members can join the RRDi by providing an email address. 

    Members who donate to the RRDi are named in public financial records unless the donor specifically instructs us that the donation is anonymous.

    Corporate Members Forum Guidelines and Privacy Policy

    The corporate members only private forum is provided as a free service of the RRDi. The institute will not release any names, mailing addresses or email addresses of who is using the private (or public) forum to any third parties without your consent.

    Privacy is important to the RRDi and you can rest assured your contact information is safe with us and we will not disclose your contact info to anyone without your permission or only if we are required by law to disclose your contact info. The privacy policy also includes the Member Forum, Blog and Gallery areas of our site as well as the Tapatalk hosted private form. The Guidelines policy is enforced and binding on all members and guests.

    Blog, Clubs and Gallery

    The Blog, Clubs and Gallery, if available, are provided as a free service by the RRDi to its members only and you are responsible for your own privacy with regard to this service if you engage with another member and disclose your private information in the Blog, Clubs or post photos in the Gallery. The RRDi cannot be held responsible for your privacy if you use the Blog, Clubs or Gallery and our privacy policy, legal disclaimer, rules, and official documents are still binding if you violate this policy.  We warn you to not disclose your private information or post inappropriate content in the Blog, Clubs or Gallery.

    The institute will not release any names or email addresses of who is using the Blog, Clubs or Gallery service without your consent.


    What are cookies and how do we use them?

    Cookies help track a person''s session while online. They are used on our site to gather basic tracking information. Cookies are not related to any personally identifiable information and are not used to retrieve information from your computer that was not originally sent in a cookie.

    Many browsers are set to accept cookies. You may prefer to set your browser to refuse cookies. It is possible, however, that some areas of the site will not function properly if you do so. This is especially likely when trying to order a publication.

    Third-Party Advertising

    Advertisements are not currently allowed on this site. If advertisements are allowed then information about your visits to this site, such as the number of times you have viewed an ad (but not your name, address, or other personal information), is used to serve ads to you. In the course of serving advertisements to this site, third-party advertisers may place or recognize unique cookies on your browser. Links to third-party advertising, or commercial web sites are prohibited.

    Amazon Affiliate

    The RRDi has joined Amazon Affiliates and links to items at amazon.com may be placed throughout the site. The RRDi receives a small fee for each item that is purchased by users who click on an item featured on our site.

    Demodex Solutions Affiliate

    The RRDi has joined the Demodex Solutions affiliate program and links to this program are placed throughout the site. The RRDi receives a small fee for each item that is purchased by users who click on an item featured on our site.


    This policy may be changed at any time at Rosacea Research & Development Institute's discretion.


    © Rosacea Research & Development Institute. All rights reserved. Reproduction, re-transmission or reprinting of the contents of this Web site, in part or in its entirety, is expressly prohibited without prior written permission from the Rosacea Research & Development Institute.

  • Member Statistics

    • Total Members
    • Most Online

    Newest Member
  • Posts

    • Front Pharmacol. 2023 Mar 1;14:1092473. doi: 10.3389/fphar.2023.1092473. eCollection 2023. ABSTRACT Background: Rosacea is a common facial skin inflammatory disease featured by hyperactivation of mTORC1 signaling in the epidermis. Due to unclear pathogenesis, the effective treatment options for rosacea remain limited. Methods: Weighted gene co-expression network analysis (WGCNA) analyzed the relationship between epidermis autophagy and mTOR pathways in rosacea, and further demonstrated it through immunofluorescence and qPCR analysis. A potential therapeutic agent for rosacea was predicted based on the key genes of the WGCNA module. In vivo and in vitro experiments were conducted to verify its therapeutic role. Drug-target prediction (TargetNet, Swiss, and Tcmsp) and molecular docking offered potential pharmacological targets. Results: WGCNA showed that epidermis autophagy was related to the activation of mTOR pathways in rosacea. Next, autophagy was downregulated in the epidermis of rosacea, which was regulated by mTOR. In addition, the in vivo experiment demonstrated that autophagy induction could be an effective treatment strategy for rosacea. Subsequently, based on the key genes of the WGCNA module, epigallocatechin-3-gallate (EGCG) was predicted as a potential therapeutic agent for rosacea. Furthermore, the therapeutic role of EGCG on rosacea was confirmed in vivo and in vitro. Finally, drug-target prediction and molecular docking revealed that AKT1/MAPK1/MMP9 could be the pharmacological targets of EGCG in rosacea. Conclusion: Collectively, our findings revealed the vital role of autophagy in rosacea and identified that EGCG, as a therapeutic agent for rosacea, attenuated rosacea-like inflammation via inducing autophagy in keratinocytes. PMID:36937834 | PMC:PMC10014537 | DOI:10.3389/fphar.2023.1092473 {url} = URL to article
    • Cureus. 2023 Feb 15;15(2):e35011. doi: 10.7759/cureus.35011. eCollection 2023 Feb. ABSTRACT The most common cutaneous manifestations of alcoholism include urticarial reaction, flushing, porphyria cutanea tarda, psoriasis, rosacea, seborrheic dermatitis, and pruritus. Here, we present a case of a young male with a history of alcohol abuse who presented with non-blanching, petechial, and perifollicular macular rash secondary to vitamin C deficiency in view of poor oral intake. The rash improved significantly with vitamin C supplementation. Although rare in developed countries, clinicians should keep vitamin C deficiency as a differential diagnosis for skin rash in alcohol consumers. PMID:36938293 | PMC:PMC10021349 | DOI:10.7759/cureus.35011 {url} = URL to article
    • J Dermatol. 2023 Mar 20. doi: 10.1111/1346-8138.16779. Online ahead of print. ABSTRACT Symptomatic dermographism (SD) is the most common form of chronic inducible urticarias. The etiology of this disease has rarely been reported in the literature. Minocycline is widely used in the treatment of acne, rosacea, and other inflammatory skin diseases. Herein we report four cases of SD onset during minocycline administration. These were young women in their 20s to 30s who were taking minocycline orally for acne vulgaris or rosacea. They all experienced the onset of SD 2-3 weeks after taking the drug, and then the complete disappearance of SD 1 month after stopping the drug. Minocycline was thought to be the culprit drug in these cases as other drugs were ruled out on clinical grounds. Our small series suggests that oral minocycline may induce SD, thus raising the awareness of this association in clinical practice. More research is needed to further confirm this association and reveal the underlying mechanism(s). PMID:36938687 | DOI:10.1111/1346-8138.16779 {url} = URL to article
    • Arch Dermatol Res. 2023 Mar 20. doi: 10.1007/s00403-023-02602-9. Online ahead of print. ABSTRACT Individuals with rosacea have different facial erythema distribution patterns; however, whether they are related to the skin type is unclear. This study enrolled 201 Chinese patients, including 195 females and six males, diagnosed with rosacea. Facial images were taken using the VISIA® Complexion Analysis System, and red-area images were further analyzed. The erythema distribution pattern of rosacea was divided into peace signs, wing shapes, and neither of the two patterns, according to the distribution location. Skin types were divided according to the Fitzpatrick skin type, and oily-dry skin subtypes were determined according to the Baumann skin-type scale. There were 130 and 44 cases of typical peace signs and typical wing shapes, respectively. The remaining 27 cases were of neither type. Among the 76 patients with peace-sign patterns, the majority (58.5%) had oily combination skin. Among the patients with a typical wing shape, 43 (97.7%) had dry combination skin. Among the 27 patients with no peace-sign or wing-shape pattern, 17 (63.0%) had dry combination skin (p < 0.05). The peace sign pattern was more common in individuals with darker skin tones (p < 0.05). The differences in the immune microenvironment, Demodex habitation, and altered lipid content may explain the presence of the peace-sign pattern in the oily combination skin population. Wing-type patterns are associated with the lateral parts of the cheeks and could be caused by abnormal vessel dilations of the anatomic branches of the zygomatic-facial and facial arteries, which indicates that the main pathogenesis for this type of rosacea may be neurovascular. Our study is the first to report that facial erythema distribution characteristics of rosacea are associated with skin types. PMID:36939880 | DOI:10.1007/s00403-023-02602-9 {url} = URL to article
    • Photobiomodul Photomed Laser Surg. 2023 Mar;41(3):104-119. doi: 10.1089/photob.2022.0120. ABSTRACT Objective: To evaluate relevant clinical outcomes and conclude possible mechanisms of intense pulsed light (IPL) in eyelid inflammation. Background: IPL devices were primarily applied in cutaneous vascular malformations and have been used in ocular diseases for about 20 years, mostly including meibomian gland dysfunction (MGD), blepharitis, and ocular rosacea. Recent findings: Seventy-two original clinical researches were included, 57 for MGD, 4 for blepharitis or blepharitis-related keratoconjunctivitis, and 11 for rosacea. Dry eye symptoms, (tear) break-up time (BUT), and meibomian structure and/or functions were improved in most patients, but production of reactive oxygen species is an important link in the photobiomodulation mediated by IPL, which can influence numerous signal pathways to achieve anti-inflammatory, anti-infective, and prodifferentiation effects. Conclusions: The evidence suggests that IPL is an effective therapeutic tool for most patients with MGD, but more clinical evidence is needed for other indications. PMID:36927050 | DOI:10.1089/photob.2022.0120 {url} = URL to article
    • Gland Surg. 2023 Feb 28;12(2):302-308. doi: 10.21037/gs-22-482. Epub 2023 Feb 3. ABSTRACT BACKGROUND: Black thyroid is a rare incidental finding during surgery. We report the case of a patient with papillary thyroid cancer who was incidentally found to have minocycline-induced black thyroid. CASE DESCRIPTION: A 29-year-old woman presented with a left thyroid nodule and metastatic papillary thyroid cancer involving the left neck level IV lymph nodes. She had a medical history of anxiety disorder with depression, severe acne, and rosacea, and had been taking benzodiazepines, selective serotonin reuptake inhibitors, isotretinoin, and minocycline for a few years. The patient underwent a total thyroidectomy with left central compartment neck dissection and ipsilateral modified radical neck dissection. A black thyroid gland was identified during thyroidectomy. During level IV dissection, we noticed a similar black discoloration in the adipose tissue of the lower neck. Pathological examination revealed brown pigmentation with few macrophages on several foci of the thyroid parenchyma. Brown pigmentation was not identified in the thyroid tumor, metastatic and normal lymph nodes, or background adipose tissue. CONCLUSIONS: We report a case of papillary thyroid microcarcinoma with cervical lymph node metastases in a black thyroid. The clinical findings were consistent with those of previous reports. Based on the literature, it remains unclear if this minocycline triggered finding is associated with an increased frequency and/or aggressiveness of thyroid carcinomas. In the absence of adequate evidence, prolonged minocycline users should ideally undergo routine thyroid assessment to identify possible malignancy. PMID:36915821 | PMC:PMC10005984 | DOI:10.21037/gs-22-482 {url} = URL to article
    • J Clin Aesthet Dermatol. 2023 Feb;16(2):24-28. ABSTRACT BACKGROUND: Photobiomodulation therapy (PBMT) can significantly reduce inflammation and relieve pain, including postoperative pain and edema. The study aimed to evaluate the performance of a photobiomodulation-based device that includes a static magnetic field (SMF) to treat laser- or intensive and fractional radiofrequency-related side effects, such as pain, redness, and edema in patients treated for different dermatological conditions. METHODS: The study had a prospective, non-randomized, single-center design. Male and female patients aged 18 years or older underwent one or two PBMT-SMF (anti-inflammatory or anti-edematous) sessions on the same day, once or twice a week, after laser or radiofrequency facial treatments due to various dermatological disorders. Variables and efficacy assessments were pain, redness, edema, and their reduction from baseline to the last visit. RESULTS: Twenty-seven patients were included, seven (25.9%) men and 20 (74.1%) women, with a mean (SD) age of 43.7 (14.1) years. Seven (25.9%) patients were treated with radiofrequency, and 20 (74.1%) patients with a vascular laser (three [15%] for angioma, two [10%] for scars, three [15%] for erythrosis, and 12 [60%] for rosacea). After the PBMT-SMF protocol, overall mean pain reduction was 40 percent, and redness and edema reduction were shown by the pictures taken before and after the PBMT-SMF procedure. LIMITATIONS: The primary limitations were the small number of patients and no quantitative variables for redness and edema. CONCLUSION: PBMT-SMF reduced edema and inflammation after treatment with lasers or intensive or fractional radiofrequency for facial conditions, and probably, analgesic and anti-inflammatory drugs. PMID:36909868 | PMC:PMC10005803 {url} = URL to article
    • Int J Pharm. 2023 Mar 11;636:122816. doi: 10.1016/j.ijpharm.2023.122816. Online ahead of print. ABSTRACT The repurposed oral use of spironolactone (SP) as an anti-rosacea drug faces many challenges that hinder its efficacy and compliance. In this study, a topically applied nanofibers (NFs) scaffold was evaluated as a promising nanocarrier that enhances SP activity and avoids the friction routine that exaggerates rosacea patients' inflamed, sensitive skin. SP-loaded poly-vinylpyrrolidone (40% PVP) nanofibers (SP-PVP NFs) were electrospun. Scanning electron microscopy showed that SP-PVP NFs have a smooth homogenous surface with a diameter of about 426.60 nm. Wettability, solid state, and mechanical properties of NFs were evaluated. Encapsulation efficiency and drug loading were 96.34% ± 1.20 and 11.89% ± 0.15, respectively. The in vitro release study showed a higher amount of SP released over pure SP with a controlled release pattern. Ex vivo results showed that the permeated amount of SP from SP-PVP NFs sheets was 4.1 times greater than that of pure SP gel. A higher percentage of SP was retained in different skin layers. Moreover, the in vivo anti-rosacea efficacy of SP-PVP NFs using croton oil challenge showed a significant reduction in erythema score compared to the pure SP. The stability and safety of NFs mats were proved, indicating that SP-PVP NFs are promising carriers of SP. PMID:36907278 | DOI:10.1016/j.ijpharm.2023.122816 {url} = URL to article
    • Int J Mol Sci. 2023 Mar 5;24(5):5001. doi: 10.3390/ijms24055001. ABSTRACT The skin, including the hypodermis, is the largest body organ and is in constant contact with the environment. Neurogenic inflammation is the result of the activity of nerve endings and mediators (neuropeptides secreted by nerve endings in the development of the inflammatory reaction in the skin), as well as interactions with other cells such as keratinocytes, Langerhans cells, endothelial cells and mast cells. The activation of TRPV-ion channels results in an increase in calcitonin gene-related peptide (CGRP) and substance P, induces the release of other pro-inflammatory mediators and contributes to the maintenance of cutaneous neurogenic inflammation (CNI) in diseases such as psoriasis, atopic dermatitis, prurigo and rosacea. Immune cells present in the skin (mononuclear cells, dendritic cells and mast cells) also express TRPV1, and their activation directly affects their function. The activation of TRPV1 channels mediates communication between sensory nerve endings and skin immune cells, increasing the release of inflammatory mediators (cytokines and neuropeptides). Understanding the molecular mechanisms underlying the generation, activation and modulation of neuropeptide and neurotransmitter receptors in cutaneous cells can aid in the development of effective treatments for inflammatory skin disorders. PMID:36902434 | PMC:PMC10003326 | DOI:10.3390/ijms24055001 {url} = URL to article
    • Molecules. 2023 Feb 24;28(5):2134. doi: 10.3390/molecules28052134. ABSTRACT Azelaic Acid (AzA) is a 9-carbon atom dicarboxylic acid, with numerous pharmacological uses in dermatology. Its effectiveness in papulopustular rosacea and acne vulgaris, among other dermatological disorders such as keratinization and hyper-pigmentation, is thought to be related to its anti-inflammatory and antimicrobial properties. It is a by-product of Pityrosporum fungal mycelia metabolism but also it is found in different cereals such as barley, wheat, and rye. Diverse topical formulations of AzA exist in commerce, and it is mainly produced via chemical synthesis. In this study we describe the extraction of AzA from whole grains and whole-grain flour (Triticum durum Desf.) through green methods. Seventeen different extracts were prepared and analyzed for their AzA content by HPLC-MS methods and then screened for their antioxidant activity using spectrophotometric assays (ABTS, DPPH, and Folin-Ciocalteu). Minimum-inhibitory-concentration (MIC) assays against several bacterial and fungal pathogens were performed, to validate their antimicrobial activity. The obtained results indicate that whole grain extracts provide a wider spectrum of activity than the flour matrix; in particular, the Naviglio® extract showed higher AzA content, while the hydroalcoholic ultrasound-assisted extract provided better antimicrobial and antioxidant activity. The data analysis was performed using principal component analysis (PCA), as an unsupervised-pattern-recognition technique, to extract useful analytical and biological information. PMID:36903378 | PMC:PMC10003986 | DOI:10.3390/molecules28052134 {url} = URL to article
    • J Affect Disord. 2023 Mar 9:S0165-0327(23)00333-6. doi: 10.1016/j.jad.2023.03.003. Online ahead of print. ABSTRACT BACKGROUND: Rosacea is a skin disease characterized by facial erythema and inflammatory pustules that may result in emotional distress. Social Phobia and Self-Esteem appear to be linked to the development of higher levels of distress in dermatological conditions, while Trait Emotional Intelligence (Trait EI) has been consistently associated with greater levels of adaptation to one's chronic condition. Hence, it seems extremely relevant to observe the interplay between these dimensions in the context of Rosacea. The goal of the current study is to test the hypothesis that an association between Trait EI and General Distress, in individuals with Rosacea would be mediated by Self-Esteem and Social Phobia. METHODS: Questionnaires were administered to 224 individuals suffering from Rosacea to assess Trait EI, Social Phobia, Self-Esteem, and General Distress. RESULTS: Results highlighted that Trait EI was positively related to Self-Esteem and negatively related to Social Phobia and General Distress. In addition, both Self-Esteem and Social Phobia showed a mediating role in the relationship between Trait EI and General Distress. LIMITATIONS: The main limitations of this work consist in the cross-sectional nature of the data, the small number of participants, also it was not possible to differentiate the participants according to the type of rosacea. DISCUSSION: These results emphasize how individuals with Rosacea may be vulnerable to internalizing states and how high levels of Trait EI may constitute a protective factor for the onset of distressing states and it would be useful to create programs aimed at fostering Trait EI in Rosacea sufferers. PMID:36906111 | DOI:10.1016/j.jad.2023.03.003 {url} = URL to article
    • Front Pain Res (Lausanne). 2023 Feb 20;4:1122134. doi: 10.3389/fpain.2023.1122134. eCollection 2023. NO ABSTRACT PMID:36890854 | PMC:PMC9986523 | DOI:10.3389/fpain.2023.1122134 {url} = URL to article
  • Create New...

Important Information

Terms of Use